Karyopharm Therapeutics Inc. Announced earnings guidance for the year 2023. Based on its current operating plans, Karyopharm is updating its guidance for full year 2023: Total revenue to be in the range of $145 million to $160 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.